The DOI matches its Crossref record; 164 of the 164 references it cites were found in a registry or an index.
Killing Mechanisms of Chimeric Antigen Receptor (CAR) T Cells
Open accessAbstract
Effective adoptive T cell therapy (ACT) comprises the killing of cancer cells through the therapeutic use of transferred T cells. One of the main ACT approaches is chimeric antigen receptor (CAR) T cell therapy. CAR T cells mediate MHC-unrestricted tumor cell killing by enabling T cells to bind target cell surface antigens through a single-chain variable fragment (scFv) recognition domain. Upon engagement, CAR T cells form a non-classical immune synapse (IS), required for their effector function. These cells then mediate their anti-tumoral effects through the perforin and granzyme axis, the Fas and Fas ligand axis, as well as the release of cytokines to sensitize the tumor stroma. Their persistence in the host and functional outputs are tightly dependent on the receptor’s individual components—scFv, spacer domain, and costimulatory domains—and how said component functions converge to augment CAR T cell performance. In this review, we bring forth the successes and limitations of CAR T cell therapy. We delve further into the current understanding of how CAR T cells are designed to function, survive, and ultimately mediate their anti-tumoral effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413 · cited 3×
“Of the 55 pediatric patients treated, 93% reached complete response (CR) (88% minimal residual disease (MRD) negative) [29,30].”
BackgroundZFN, TALEN, and CRISPR/Cas-based methods for genome engineering
Gaj, T., Gersbach, C. A., & Barbas, C. F. (2013) · Trends in Biotechnology · doi:10.1016/j.tibtech.2013.04.004 · Cited by 3,820
Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509
Lee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., Feldman, S. A., Fry, T. J., Orentas, R., Sabatino, M., Shah, N. N., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61403-3 · Cited by 2,898
Morgan, R. A., Yang, J. C., Kitano, M., Dudley, M. E., Laurencot, C. M., & Rosenberg, S. A. (2010) · Molecular Therapy · doi:10.1038/mt.2010.24 · Cited by 2,533
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Davila, M. L., Riviere, I., Wang, X., Bartido, S., Park, J., Curran, K., Chung, S. S., Stefanski, J., Borquez-Ojeda, O., Olszewska, M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008226 · Cited by 2,476
Chimeric antigen receptor T-cell therapy—assessment and management of toxicities
Neelapu, S. S., Tummala, S., Kebriaei, P., Wierda, W., Gutierrez, C., Locke, F. L., Komanduri, K. V., Lin, Y., Jain, N., Daver, N., et al. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.148 · Cited by 2,438
Rosenberg, S. A., Yang, J. C., Sherry, R. M., Kammula, U. S., Hughes, M. S., Phan, G. Q., Citrin, D. E., Restifo, N. P., Robbins, P. F., Wunderlich, J. R., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0116 · Cited by 2,140
Three-dimensional segregation of supramolecular activation clusters in T cells
Monks, C. R. F., Freiberg, B. A., Kupfer, H., Sciaky, N., & Kupfer, A. (1998) · Nature · doi:10.1038/25764 · Cited by 1,968
Humanization of an anti-p185HER2 antibody for human cancer therapy.
Carter, P., Presta, L., Gorman, C. M., Ridgway, J. B., Henner, D., Wong, W. L., Rowland, A. M., Kotts, C., Carver, M. E., & Shepard, H. M. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.10.4285 · Cited by 1,918
Targeting DNA Double-Strand Breaks with TAL Effector Nucleases
Christian, M., Cermak, T., Doyle, E. L., Schmidt, C., Zhang, F., Hummel, A., Bogdanove, A. J., & Voytas, D. F. (2010) · Genetics · doi:10.1534/genetics.110.120717 · Cited by 1,869
Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
Brown, C. E., Alizadeh, D., Starr, R., Weng, L., Wagner, J. R., Naranjo, A., Ostberg, J. R., Blanchard, M. S., Kilpatrick, J., Simpson, J., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1610497 · Cited by 1,836
Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection
Eyquem, J., Mansilla-Soto, J., Giavridis, T., van der Stegen, S. J. C., Hamieh, M., Cunanan, K. M., Odak, A., Gönen, M., & Sadelain, M. (2017) · Nature · doi:10.1038/nature21405 · Cited by 1,831 · cited 1×
“Signaling domain configurations, spacer length [117], and gene transfer approaches that could impact CAR expression levels on the T cell surface must be considered [118,119].”
BackgroundLong, A. H., Haso, W. M., Shern, J. F., Wanhainen, K. M., Murgai, M., Ingaramo, M., Smith, J. P., Walker, A. J., Kohler, M. E., Venkateshwara, V. R., et al. (2015) · Nature Medicine · doi:10.1038/nm.3838 · Cited by 1,815
Fraietta, J. A., Lacey, S. F., Orlando, E. J., Pruteanu-Malinici, I., Gohil, M., Lundh, S., Boesteanu, A. C., Wang, Y., O’Connor, R. S., Hwang, W.-T., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0010-1 · Cited by 1,785
Kägi, D., Ledermann, B., Bürki, K., Seiler, P., Odermatt, B., Olsen, K. J., Podack, E. R., Zinkernagel, R. M., & Hengartner, H. (1994) · Nature · doi:10.1038/369031a0 · Cited by 1,757
Eshhar, Z., Waks, T., Gross, G., & Schindler, D. G. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.2.720 · Cited by 1,658
CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes
Janssen, E. M., Lemmens, E. E., Wolfe, T., Christen, U., von Herrath, M. G., & Schoenberger, S. P. (2003) · Nature · doi:10.1038/nature01441 · Cited by 1,635
Fas and Perforin Pathways as Major Mechanisms of T Cell-Mediated Cytotoxicity
Kägi, D., Vignaux, F., Ledermann, B., Bürki, K., Depraetere, V., Nagata, S., Hengartner, H., & Golstein, P. (1994) · Science · doi:10.1126/science.7518614 · Cited by 1,516
Norelli, M., Camisa, B., Barbiera, G., Falcone, L., Purevdorj, A., Genua, M., Sanvito, F., Ponzoni, M., Doglioni, C., Cristofori, P., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0036-4 · Cited by 1,406
The Central Role of CD4+ T Cells in the Antitumor Immune Response
Hung, K., Hayashi, R., Lafond-Walker, A., Lowenstein, C., Pardoll, D., & Levitsky, H. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.12.2357 · Cited by 1,345
Fry, T. J., Shah, N. N., Orentas, R. J., Stetler-Stevenson, M., Yuan, C. M., Ramakrishna, S., Wolters, P., Martin, S., Delbrook, C., Yates, B., et al. (2018) · Nature Medicine · doi:10.1038/nm.4441 · Cited by 1,335
CAR T cell–induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade
Giavridis, T., van der Stegen, S. J. C., Eyquem, J., Hamieh, M., Piersigilli, A., & Sadelain, M. (2018) · Nature Medicine · doi:10.1038/s41591-018-0041-7 · Cited by 1,272
A Phase I Study on Adoptive Immunotherapy Using Gene-Modified T Cells for Ovarian Cancer
Kershaw, M. H., Westwood, J. A., Parker, L. L., Wang, G., Eshhar, Z., Mavroukakis, S. A., White, D. E., Wunderlich, J. R., Canevari, S., Rogers-Freezer, L., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1183 · Cited by 1,254
Tumor Antigen Escape from CAR T-cell Therapy
Majzner, R. G., & Mackall, C. L. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0442 · Cited by 1,183
Linette, G. P., Stadtmauer, E. A., Maus, M. V., Rapoport, A. P., Levine, B. L., Emery, L., Litzky, L., Bagg, A., Carreno, B. M., Cimino, P. J., et al. (2013) · Blood · doi:10.1182/blood-2013-03-490565 · Cited by 1,179
Cancer Regression and Neurological Toxicity Following Anti-MAGE-A3 TCR Gene Therapy
Morgan, R. A., Chinnasamy, N., Abate-Daga, D., Gros, A., Robbins, P. F., Zheng, Z., Dudley, M. E., Feldman, S. A., Yang, J. C., Sherry, R. M., et al. (2013) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3182829903 · Cited by 1,148
Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways
Lowin, B., Hahne, M., Mattmann, C., & Tschopp, J. (1994) · Nature · doi:10.1038/370650a0 · Cited by 1,051
Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ /CD28 receptor
Maher, J., Brentjens, R. J., Gunset, G., Rivière, I., & Sadelain, M. (2002) · Nature Biotechnology · doi:10.1038/nbt0102-70 · Cited by 1,034
Parkhurst, M. R., Yang, J. C., Langan, R. C., Dudley, M. E., Nathan, D.-A. N., Feldman, S. A., Davis, J. L., Morgan, R. A., Merino, M. J., Sherry, R. M., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2010.272 · Cited by 1,020
Precision Tumor Recognition by T Cells With Combinatorial Antigen-Sensing Circuits
Roybal, K. T., Rupp, L. J., Morsut, L., Walker, W. J., McNally, K. A., Park, J. S., & Lim, W. A. (2016) · Cell · doi:10.1016/j.cell.2016.01.011 · Cited by 1,000
Lamers, C. H. J., Sleijfer, S., Vulto, A. G., Kruit, W. H. J., Kliffen, M., Debets, R., Gratama, J. W., Stoter, G., & Oosterwijk, E. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.05.9964 · Cited by 915
Toxicity and management in CAR T-cell therapy
Bonifant, C. L., Jackson, H. J., Brentjens, R. J., & Curran, K. J. (2016) · Molecular Therapy - Oncolytics · doi:10.1038/mto.2016.11 · Cited by 885
The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand.
O'Connell, J., O'Sullivan, G. C., Collins, J. K., & Shanahan, F. (1996) · The Journal of experimental medicine · doi:10.1084/jem.184.3.1075 · Cited by 878
Identification of essential genes for cancer immunotherapy
Patel, S. J., Sanjana, N. E., Kishton, R. J., Eidizadeh, A., Vodnala, S. K., Cam, M., Gartner, J. J., Jia, L., Steinberg, S. M., Yamamoto, T. N., et al. (2017) · Nature · doi:10.1038/nature23477 · Cited by 870
Sommermeyer, D., Hudecek, M., Kosasih, P. L., Gogishvili, T., Maloney, D. G., Turtle, C. J., & Riddell, S. R. (2016) · Leukemia · doi:10.1038/leu.2015.247 · Cited by 867
Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo
Rafiq, S., Yeku, O. O., Jackson, H. J., Purdon, T. J., van Leeuwen, D. G., Drakes, D. J., Song, M., Miele, M. M., Li, Z., Wang, P., et al. (2018) · Nature Biotechnology · doi:10.1038/nbt.4195 · Cited by 833
Adachi, K., Kano, Y., Nagai, T., Okuyama, N., Sakoda, Y., & Tamada, K. (2018) · Nature Biotechnology · doi:10.1038/nbt.4086 · Cited by 792
Antony, P. A., Piccirillo, C. A., Akpinarli, A., Finkelstein, S. E., Speiss, P. J., Surman, D. R., Palmer, D. C., Chan, C.-C., Klebanoff, C. A., Overwijk, W. W., et al. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.5.2591 · Cited by 760
Rupp, L. J., Schumann, K., Roybal, K. T., Gate, R. E., Ye, C. J., Lim, W. A., & Marson, A. (2017) · Scientific Reports · doi:10.1038/s41598-017-00462-8 · Cited by 757
Fedorov, V. D., Themeli, M., & Sadelain, M. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006597 · Cited by 735
CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia
Maude, S. L., Teachey, D. T., Porter, D. L., & Grupp, S. A. (2015) · Blood · doi:10.1182/blood-2014-12-580068 · Cited by 727
How Do Cytotoxic Lymphocytes Kill Cancer Cells?
Martínez-Lostao, L., Anel, A., & Pardo, J. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0685 · Cited by 717
Remote control of therapeutic T cells through a small molecule–gated chimeric receptor
Wu, C.-Y., Roybal, K. T., Puchner, E. M., Onuffer, J., & Lim, W. A. (2015) · Science · doi:10.1126/science.aab4077 · Cited by 687
Universal Chimeric Antigen Receptors for Multiplexed and Logical Control of T Cell Responses
Cho, J. H., Collins, J. J., & Wong, W. W. (2018) · Cell · doi:10.1016/j.cell.2018.03.038 · Cited by 682
Pegram, H. J., Lee, J. C., Hayman, E. G., Imperato, G. H., Tedder, T. F., Sadelain, M., & Brentjens, R. J. (2012) · Blood · doi:10.1182/blood-2011-12-400044 · Cited by 678
Brentjens, R. J., Latouche, J.-B., Santos, E., Marti, F., Gong, M. C., Lyddane, C., King, P. D., Larson, S., Weiss, M., Rivière, I., et al. (2003) · Nature Medicine · doi:10.1038/nm827 · Cited by 669
Kagoya, Y., Tanaka, S., Guo, T., Anczurowski, M., Wang, C.-H., Saso, K., Butler, M. O., Minden, M. D., & Hirano, N. (2018) · Nature Medicine · doi:10.1038/nm.4478 · Cited by 622
Structural Basis for Sequence-Specific Recognition of DNA by TAL Effectors
Deng, D., Yan, C., Pan, X., Mahfouz, M., Wang, J., Zhu, J.-K., Shi, Y., & Yan, N. (2012) · Science · doi:10.1126/science.1215670 · Cited by 601
Centrosome polarization delivers secretory granules to the immunological synapse
Stinchcombe, J. C., Majorovits, E., Bossi, G., Fuller, S., & Griffiths, G. M. (2006) · Nature · doi:10.1038/nature05071 · Cited by 599
The Two Faces of Interferon-γ in Cancer
Zaidi, M. R., & Merlino, G. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0482 · Cited by 593
Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation
Guedan, S., Posey, A. D., Shaw, C., Wing, A., Da, T., Patel, P. R., McGettigan, S. E., Casado-Medrano, V., Kawalekar, O. U., Uribe-Herranz, M., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.96976 · Cited by 580
Zhang, C., Liu, J., Zhong, J. F., & Zhang, X. (2017) · Biomarker Research · doi:10.1186/s40364-017-0102-y · Cited by 578
Liu, X., Jiang, S., Fang, C., Yang, S., Olalere, D., Pequignot, E. C., Cogdill, A. P., Li, N., Ramones, M., Granda, B., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0159 · Cited by 565
The determination and interpretation of the therapeutic index in drug development
Muller, P. Y., & Milton, M. N. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3801 · Cited by 563
Di Stasi, A., De Angelis, B., Rooney, C. M., Zhang, L., Mahendravada, A., Foster, A. E., Heslop, H. E., Brenner, M. K., Dotti, G., & Savoldo, B. (2009) · Blood · doi:10.1182/blood-2009-03-209650 · Cited by 533
Torikai, H., Reik, A., Liu, P.-Q., Zhou, Y., Zhang, L., Maiti, S., Huls, H., Miller, J. C., Kebriaei, P., Rabinovitch, B., et al. (2012) · Blood · doi:10.1182/blood-2012-01-405365 · Cited by 528
Craddock, J. A., Lu, A., Bear, A., Pule, M., Brenner, M. K., Rooney, C. M., & Foster, A. E. (2010) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181ee6675 · Cited by 513
Programmed cell death and the immune system
Nagata, S., & Tanaka, M. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2016.153 · Cited by 512
Complex Complexes: Signaling at the TCR
Wange, R. L., & Samelson, L. E. (1996) · Immunity · doi:10.1016/s1074-7613(00)80315-5 · Cited by 511
Signal 3 Determines Tolerance versus Full Activation of Naive CD8 T Cells
Curtsinger, J. M., Lins, D. C., & Mescher, M. F. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20021910 · Cited by 509
Design and development of therapies using chimeric antigen receptor‐expressing T cells
Dotti, G., Gottschalk, S., Savoldo, B., & Brenner, M. K. (2014) · Immunological Reviews · doi:10.1111/imr.12131 · Cited by 508
Dustin, M. L. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0161 · Cited by 502
Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells
Kebriaei, P., Singh, H., Huls, M. H., Figliola, M. J., Bassett, R., Olivares, S., Jena, B., Dawson, M. J., Kumaresan, P. R., Su, S., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci86721 · Cited by 500
Salter, A. I., Ivey, R. G., Kennedy, J. J., Voillet, V., Rajan, A., Alderman, E. J., Voytovich, U. J., Lin, C., Sommermeyer, D., Liu, L., et al. (2018) · Science Signaling · doi:10.1126/scisignal.aat6753 · Cited by 495
Engineering CAR-T cells: Design concepts
Srivastava, S., & Riddell, S. R. (2015) · Trends in Immunology · doi:10.1016/j.it.2015.06.004 · Cited by 485
Chow, M. T., & Luster, A. D. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0160 · Cited by 485
TanCAR: A Novel Bispecific Chimeric Antigen Receptor for Cancer Immunotherapy
Grada, Z., Hegde, M., Byrd, T., Shaffer, D. R., Ghazi, A., Brawley, V. S., Corder, A., Schönfeld, K., Koch, J., Dotti, G., et al. (2013) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2013.32 · Cited by 458
Molecular mechanisms of biogenesis and exocytosis of cytotoxic granules
de Saint Basile, G., Ménasché, G., & Fischer, A. (2010) · Nature Reviews Immunology · doi:10.1038/nri2803 · Cited by 446
Teaching an old dog new tricks: next-generation CAR T cells
Tokarew, N., Ogonek, J., Endres, S., von Bergwelt-Baildon, M., & Kobold, S. (2019) · British Journal of Cancer · doi:10.1038/s41416-018-0325-1 · Cited by 440
Self-citationProgramming CAR-T cells to kill cancer
Labanieh, L., Majzner, R. G., & Mackall, C. L. (2018) · Nature Biomedical Engineering · doi:10.1038/s41551-018-0235-9 · Cited by 431
Adoptive cellular therapy: A race to the finish line
June, C. H., Riddell, S. R., & Schumacher, T. N. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa3643 · Cited by 403
CAR-T cells: the long and winding road to solid tumors
D’Aloia, M. M., Zizzari, I. G., Sacchetti, B., Pierelli, L., & Alimandi, M. (2018) · Cell Death & Disease · doi:10.1038/s41419-018-0278-6 · Cited by 399
A versatile system for rapid multiplex genome-edited CAR T cell generation
Ren, J., Zhang, X., Liu, X., Fang, C., Jiang, S., June, C. H., & Zhao, Y. (2017) · Oncotarget · doi:10.18632/oncotarget.15218 · Cited by 397
Gargett, T., & Brown, M. P. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00235 · Cited by 395
DNA methyltransferases and their roles in tumorigenesis
Zhang, W., & Xu, J. (2017) · Biomarker Research · doi:10.1186/s40364-017-0081-z · Cited by 382
Tumor immune evasion arises through loss of TNF sensitivity
Kearney, C. J., Vervoort, S. J., Hogg, S. J., Ramsbottom, K. M., Freeman, A. J., Lalaoui, N., Pijpers, L., Michie, J., Brown, K. K., Knight, D. A., et al. (2018) · Science Immunology · doi:10.1126/sciimmunol.aar3451 · Cited by 381
Silencing and Variegation of Gammaretrovirus and Lentivirus Vectors
Ellis, J. (2005) · Human Gene Therapy · doi:10.1089/hum.2005.16.1241 · Cited by 379
Fas antigen is the major target molecule for CD4+ T cell-mediated cytotoxicity.
Stalder, T., Hahn, S., & Erb, P. (1994) · The Journal of Immunology · doi:10.4049/jimmunol.152.3.1127 · Cited by 373
Kramer, J. A., Sagartz, J. E., & Morris, D. L. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2378 · Cited by 372
Lamers, C. H. J., Willemsen, R., van Elzakker, P., van Steenbergen-Langeveld, S., Broertjes, M., Oosterwijk-Wakka, J., Oosterwijk, E., Sleijfer, S., Debets, R., & Gratama, J. W. (2011) · Blood · doi:10.1182/blood-2010-07-294520 · Cited by 368
Krause, A., Guo, H.-F., Latouche, J.-B., Tan, C., Cheung, N.-K. V., & Sadelain, M. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.4.619 · Cited by 365
The role of CD95 and CD95 ligand in cancer
Peter, M. E., Hadji, A., Murmann, A. E., Brockway, S., Putzbach, W., Pattanayak, A., & Ceppi, P. (2015) · Cell Death & Differentiation · doi:10.1038/cdd.2015.3 · Cited by 357
Chmielewski, M., Hombach, A. A., & Abken, H. (2014) · Immunological Reviews · doi:10.1111/imr.12125 · Cited by 356
ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells
Guedan, S., Chen, X., Madar, A., Carpenito, C., McGettigan, S. E., Frigault, M. J., Lee, J., Posey, A. D., Scholler, J., Scholler, N., et al. (2014) · Blood · doi:10.1182/blood-2013-10-535245 · Cited by 353
Davenport, A. J., Cross, R. S., Watson, K. A., Liao, Y., Shi, W., Prince, H. M., Beavis, P. A., Trapani, J. A., Kershaw, M. H., Ritchie, D. S., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1716266115 · Cited by 351
IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors
Kerkar, S. P., Goldszmid, R. S., Muranski, P., Chinnasamy, D., Yu, Z., Reger, R. N., Leonardi, A. J., Morgan, R. A., Wang, E., Marincola, F. M., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci58814 · Cited by 342
A T-cell–directed chimeric antigen receptor for the selective treatment of T-cell malignancies
Mamonkin, M., Rouce, R. H., Tashiro, H., & Brenner, M. K. (2015) · Blood · doi:10.1182/blood-2015-02-629527 · Cited by 335
Biophysical mechanism of T-cell receptor triggering in a reconstituted system
James, J. R., & Vale, R. D. (2012) · Nature · doi:10.1038/nature11220 · Cited by 323
Cell death induced by the Fas/Fas ligand pathway and its role in pathology
Waring, P., & Müllbacher, A. (1999) · Immunology & Cell Biology · doi:10.1046/j.1440-1711.1999.00837.x · Cited by 322
Toward eliminating HLA class I expression to generate universal cells from allogeneic donors
Torikai, H., Reik, A., Soldner, F., Warren, E. H., Yuen, C., Zhou, Y., Crossland, D. L., Huls, H., Littman, N., Zhang, Z., et al. (2013) · Blood · doi:10.1182/blood-2013-03-478255 · Cited by 311
Hombach, A., Wieczarkowiecz, A., Marquardt, T., Heuser, C., Usai, L., Pohl, C., Seliger, B., & Abken, H. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.11.6123 · Cited by 299
Mechanisms of granule-dependent killing
Cullen, S. P., & Martin, S. J. (2008) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4402244 · Cited by 285
Gomes-Silva, D., Mukherjee, M., Srinivasan, M., Krenciute, G., Dakhova, O., Zheng, Y., Cabral, J. M. S., Rooney, C. M., Orange, J. S., Brenner, M. K., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.09.015 · Cited by 285
Krogsgaard, M., & Davis, M. M. (2005) · Nature Immunology · doi:10.1038/ni1173 · Cited by 280
Targeted antibody-mediated depletion of murine CD19 CAR T cells permanently reverses B cell aplasia
Paszkiewicz, P. J., Fräßle, S. P., Srivastava, S., Sommermeyer, D., Hudecek, M., Drexler, I., Sadelain, M., Liu, L., Jensen, M. C., Riddell, S. R., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci84813 · Cited by 276
Tumor Eradication by Adoptive Transfer of Cytototic T Lymphocytes
(1992) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)60294-8 · Cited by 275
Chmielewski, M., Hombach, A., Heuser, C., Adams, G. P., & Abken, H. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.12.7647 · Cited by 260
Jenkins, M. R., Rudd-Schmidt, J. A., Lopez, J. A., Ramsbottom, K. M., Mannering, S. I., Andrews, D. M., Voskoboinik, I., & Trapani, J. A. (2015) · Journal of Experimental Medicine · doi:10.1084/jem.20140964 · Cited by 258
Adoptive T Cell Therapies: A Comparison of T Cell Receptors and Chimeric Antigen Receptors
Harris, D. T., & Kranz, D. M. (2016) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.11.004 · Cited by 257
Kerkar, S. P., Muranski, P., Kaiser, A., Boni, A., Sanchez-Perez, L., Yu, Z., Palmer, D. C., Reger, R. N., Borman, Z. A., Zhang, L., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0735 · Cited by 254
James, S. E., Greenberg, P. D., Jensen, M. C., Lin, Y., Wang, J., Till, B. G., Raubitschek, A. A., Forman, S. J., & Press, O. W. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.10.7028 · Cited by 249
Boyiadzis, M. M., Dhodapkar, M. V., Brentjens, R. J., Kochenderfer, J. N., Neelapu, S. S., Maus, M. V., Porter, D. L., Maloney, D. G., Grupp, S. A., Mackall, C. L., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0460-5 · Cited by 246
Zhong, S., Malecek, K., Johnson, L. A., Yu, Z., Vega-Saenz de Miera, E., Darvishian, F., McGary, K., Huang, K., Boyer, J., Corse, E., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1221609110 · Cited by 245
Death Receptor-Ligand Systems in Cancer, Cell Death, and Inflammation
Walczak, H. (2013) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a008698 · Cited by 242
CRISPR-Cas9 mediated LAG-3 disruption in CAR-T cells
Zhang, Y., Zhang, X., Cheng, C., Mu, W., Liu, X., Li, N., Wei, X., Liu, X., Xia, C., & Wang, H. (2017) · Frontiers of Medicine · doi:10.1007/s11684-017-0543-6 · Cited by 239
Bioengineering T cells to target carbohydrate to treat opportunistic fungal infection
Kumaresan, P. R., Manuri, P. R., Albert, N. D., Maiti, S., Singh, H., Mi, T., Roszik, J., Rabinovich, B., Olivares, S., Krishnamurthy, J., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1312789111 · Cited by 237
Strategies to Address Chimeric Antigen Receptor Tonic Signaling
Ajina, A., & Maher, J. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-1097 · Cited by 237
The Toxicology of Interleukin-12: A Review
Car, B. D., Eng, V. M., Lipman, J. M., & Anderson, T. D. (1999) · Toxicologic Pathology · doi:10.1177/019262339902700112 · Cited by 220
Evidence for a TCR Affinity Threshold Delimiting Maximal CD8 T Cell Function
Schmid, D. A., Irving, M. B., Posevitz, V., Hebeisen, M., Posevitz-Fejfar, A., Sarria, J.-C. F., Gomez-Eerland, R., Thome, M., Schumacher, T. N. M., Romero, P., et al. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1000173 · Cited by 219
A Transposon and Transposase System for Human Application
Hackett, P. B., Largaespada, D. A., & Cooper, L. J. (2010) · Molecular Therapy · doi:10.1038/mt.2010.2 · Cited by 206
Designing chimeric antigen receptors to effectively and safely target tumors
Jensen, M. C., & Riddell, S. R. (2015) · Current Opinion in Immunology · doi:10.1016/j.coi.2015.01.002 · Cited by 204
ITAM-mediated Signaling by the T-Cell Antigen Receptor
Love, P. E., & Hayes, S. M. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a002485 · Cited by 196
Structural Basis and Functional Role of Intramembrane Trimerization of the Fas/CD95 Death Receptor
Fu, Q., Fu, T.-M., Cruz, A. C., Sengupta, P., Thomas, S. K., Wang, S., Siegel, R. M., Wu, H., & Chou, J. J. (2016) · Molecular Cell · doi:10.1016/j.molcel.2016.01.009 · Cited by 191
Künkele, A., Johnson, A. J., Rolczynski, L. S., Chang, C. A., Hoglund, V., Kelly-Spratt, K. S., & Jensen, M. C. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0200 · Cited by 182
Harris, D. T., Hager, M. V., Smith, S. N., Cai, Q., Stone, J. D., Kruger, P., Lever, M., Dushek, O., Schmitt, T. M., Greenberg, P. D., et al. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1700236 · Cited by 182
Approved CAR T cell therapies: ice bucket challenges on glaring safety risks and long-term impacts
Zheng, P.-P., Kros, J. M., & Li, J. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.02.012 · Cited by 171
CAR-T Cells Inflict Sequential Killing of Multiple Tumor Target Cells
Davenport, A. J., Jenkins, M. R., Cross, R. S., Yong, C. S. M., Prince, H. M., Ritchie, D. S., Trapani, J. A., Kershaw, M. H., Darcy, P. K., & Neeson, P. J. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0048 · Cited by 164
Enhancing Tumor T Cell Infiltration to Enable Cancer Immunotherapy
Zhang, J., Endres, S., & Kobold, S. (2019) · Immunotherapy · doi:10.2217/imt-2018-0111 · Cited by 158
Self-citationImmunological Synapse Predicts Effectiveness of Chimeric Antigen Receptor Cells
Xiong, W., Chen, Y., Kang, X., Chen, Z., Zheng, P., Hsu, Y.-H., Jang, J. H., Qin, L., Liu, H., Dotti, G., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.01.020 · Cited by 157
Hassin, D., Garber, O. G., Meiraz, A., Schiffenbauer, Y. S., & Berke, G. (2011) · Immunology · doi:10.1111/j.1365-2567.2011.03426.x · Cited by 143
Tatsumi, T., Huang, J., Gooding, W. E., Gambotto, A. A., Robbins, P. D., Vujanović, N. L., Alber, S. M., Watkins, S. C., Okada, H., & Storkus, W. J. (2003) · PubMed · Cited by 140
Haynes, N. M., Snook, M. B., Trapani, J. A., et al. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.1.182 · Cited by 139
Tanchot, C., Terme, M., Pere, H., Tran, T., Benhamouda, N., Strioga, M., Banissi, C., Galluzzi, L., Kroemer, G., & Tartour, E. (2013) · Cancer Microenvironment · doi:10.1007/s12307-012-0122-y · Cited by 138
Yasukawa, M., Ohminami, H., Arai, J. A., Kasahara, Y., Ishida, Y., & Fujita, S. (2000) · Blood · doi:10.1182/blood.v95.7.2352 · Cited by 138
Marcucci, K. T., Jadlowsky, J. K., Hwang, W., Suhoski, M. M., Gonzalez, V. E., Kulikovskaya, I. M., Gupta, M., Lacey, S. F., Plesa, G., Chew, A., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.10.012 · Cited by 138
Imaging burst kinetics and spatial coordination during serial killing by single natural killer cells
Choi, P. J., & Mitchison, T. J. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1221312110 · Cited by 133
Role of Calcium Influx in Cytotoxic T Lymphocyte Lytic Granule Exocytosis during Target Cell Killing
Lyubchenko, T. A., Wurth, G. A., & Zweifach, A. (2001) · Immunity · doi:10.1016/s1074-7613(01)00233-3 · Cited by 125
Human Tumor Antigens Yesterday, Today, and Tomorrow
Finn, O. J. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0112 · Cited by 119
Evidence from in vitro studies that tolerance to self antigens is MHC-restricted
Rammensee, H., & Bevan, M. J. (1984) · Nature · doi:10.1038/308741a0 · Cited by 117
A Multidrug-resistant Engineered CAR T Cell for Allogeneic Combination Immunotherapy
Valton, J., Guyot, V., Maréchal, A., Filhol, J.-M., Juillerat, A., Duclert, A., Duchateau, P. N., & Poirot, L. (2015) · Molecular Therapy · doi:10.1038/mt.2015.104 · Cited by 114
Liadi, I., Singh, H., Romain, G., Rey-Villamizar, N., Merouane, A., Adolacion, J. R. T., Kebriaei, P., Huls, H. M., Qiu, P., Roysam, B., et al. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0195 · Cited by 102
Challenges and opportunities of allogeneic donor-derived CAR T cells
Yang, Y., Jacoby, E., & Fry, T. J. (2015) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000181 · Cited by 101
Zhao, Z., Shi, L., Zhang, W., Han, J., Zhang, S., Fu, Z., & Cai, J. (2017) · Oncotarget · doi:10.18632/oncotarget.23730 · Cited by 101
Combinatorial antibody libraries: new advances, new immunological insights
Lerner, R. A. (2016) · Nature reviews. Immunology · doi:10.1038/nri.2016.67 · Cited by 99
Switchable control over in vivo CAR T expansion, B cell depletion, and induction of memory
Viaud, S., Ma, J. S. Y., Hardy, I. R., Hampton, E. N., Benish, B., Sherwood, L., Núñez, V., Ackerman, C. J., Khialeeva, E., Weglarz, M., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1810060115 · Cited by 99
Waterhouse, N. J., Sutton, V. R., Sedelies, K. A., Ciccone, A., Jenkins, M. R., Turner, S. J., Bird, P. I., & Trapani, J. A. (2006) · The Journal of Cell Biology · doi:10.1083/jcb.200510072 · Cited by 97
Koehler, H., Kofler, D. M., Hombach, A. A., & Abken, H. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2098 · Cited by 95
van Herpen, C. M. L., van der Laak, J., de Vries, I. J. M., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1524 · Cited by 94
Preassembled zinc-finger arrays for rapid construction of ZFNs
Kim, S., Lee, M., Kim, H., Kang, M., & Kim, J. (2010) · Nature Methods · doi:10.1038/nmeth0111-7a · Cited by 90
Efficacy of CAR T-cell Therapy in Large Tumors Relies upon Stromal Targeting by IFNγ
Textor, A., Listopad, J. J., Wührmann, L. L., Pérez, C., Kruschinski, A., Chmielewski, M. M., Abken, H., Blankenstein, T. J. F., & Charo, J. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0079 · Cited by 88
Omiya, R., Buteau, C., Kobayashi, H., Payá, C. V., & Celis, E. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.4.2172 · Cited by 87
Hong, L. K., Chen, Y., Smith, C. C., Montgomery, S. A., Vincent, B. G., Dotti, G., & Savoldo, B. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0065 · Cited by 85
PD-L1 and IAPs co-operate to protect tumors from cytotoxic lymphocyte-derived TNF
Kearney, C. J., Lalaoui, N., Freeman, A. J., Ramsbottom, K. M., Silke, J., & Oliaro, J. (2017) · Cell Death & Differentiation · doi:10.1038/cdd.2017.94 · Cited by 83
Hombach, A. A., Köhler, H., Rappl, G., & Abken, H. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.8.5668 · Cited by 82
Erratum: The role of CD95 and CD95 ligand in cancer
Peter, M. E., Hadji, A., Murmann, A. E., Brockway, S., Putzbach, W., Pattanayak, A., & Ceppi, P. (2015) · Cell Death and Differentiation · doi:10.1038/cdd.2015.25 · Cited by 79
Rapp, M., Grassmann, S. A., Chaloupka, M., Layritz, P., Krüger, S., Ormanns, S., Rataj, F., Janssen, K., Endres, S., Anz, D., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1105428 · Cited by 76
Self-citationMaude, S. L., Barrett, D. M., Rheingold, S. R., Aplenc, R., Teachey, D. T., Callahan, C. A., Baniewicz, D., White, C., Talekar, M. K., Shaw, P. A., et al. (2016) · Blood · doi:10.1182/blood.v128.22.217.217 · Cited by 76
Minicircle DNA electrotransfer for efficient tissue-targeted gene delivery
Chabot, S., Orio, J., Schmeer, M., Schleef, M., Golzio, M., & Teissié, J. (2012) · Gene Therapy · doi:10.1038/gt.2011.215 · Cited by 75
Meiraz, A., Garber, O. G., Harari, S., Hassin, D., & Berke, G. (2009) · Immunology · doi:10.1111/j.1365-2567.2009.03072.x · Cited by 74
Fas Ligand on Tumor Cells Mediates Inactivation of Neutrophils
Chen, Y.-L., Chen, S., Wang, J., & Yang, B.-C. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.3.1183 · Cited by 70
Witting, S. R., Vallanda, P., & Gamble, A. (2013) · Gene Therapy · doi:10.1038/gt.2013.23 · Cited by 58
Simpson-Abelson, M. R., Purohit, V. S., Pang, W. M., Iyer, V., Odunsi, K. O., Demmy, T. L., Yokota, S. J., Loyall, J. L., Kelleher, R. J., Balu‐Iyer, S. V., et al. (2009) · Clinical Immunology · doi:10.1016/j.clim.2009.03.516 · Cited by 51
Bachmann, D., Aliperta, R., Bergmann, R., Feldmann, A., Koristka, S., Arndt, C., Loff, S., Welzel, P. B., Albert, S., Kegler, A., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.23556 · Cited by 49
Geiger, T. L., Leitenberg, D., & Flavell, R. A. (1999) · PubMed · Cited by 47
He, J.-C., Zhang, Z., Lv, S., Liu, X., Cui, L., Jiang, D., Zhang, Q., Li, L., Qin, W., Jin, H., et al. (2018) · Cellular Immunology · doi:10.1016/j.cellimm.2018.04.007 · Cited by 46
Selective Bispecific T Cell Recruiting Antibody and Antitumor Activity of Adoptive T Cell Transfer
Kobold, S., Steffen, J., Chaloupka, M., Grassmann, S. A., Henkel, J., Castoldi, R., Zeng, Y., Chmielewski, M. M., Schmollinger, J. C., Schnurr, M. M., et al. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju364 · Cited by 43
Self-citationGeiger, T. L., Leitenberg, D., & Flavell, R. A. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.10.5931 · Cited by 42
Rataj, F., Kraus, F. B. T., Chaloupka, M., Grassmann, S. A., Heise, C., Cadilha, B. L., Duewell, P., Endres, S., & Kobold, S. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01955 · Cited by 31
Self-citationEnabling T Cell Recruitment to Tumours as a Strategy for Improving Adoptive T Cell Therapy
Cadilha, B. L., Dorman, K., Rataj, F., Endres, S., & Kobold, S. (2017) · European Oncology & Haematology · doi:10.17925/eoh.2017.13.01.66 · Cited by 10
Self-citation
Cited by
Cytotoxic CD8+ T cells in cancer and cancer immunotherapy
Raskov, H., Orhan, A., Christensen, J. P., & Gögenur, I. (2021) · British Journal of Cancer · doi:10.1038/s41416-020-01048-4 · Cited by 1,687
Recent advances and discoveries in the mechanisms and functions of CAR T cells
Larson, R. C., & Maus, M. V. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-020-00323-z · Cited by 852
Ionizable Lipid Nanoparticle-Mediated mRNA Delivery for Human CAR T Cell Engineering
Billingsley, M. M., Singh, N., Ravikumar, P., Zhang, R., June, C. H., & Mitchell, M. J. (2020) · Nano Letters · doi:10.1021/acs.nanolett.9b04246 · Cited by 636
Maalej, K. M., Merhi, M., Inchakalody, V. P., Mestiri, S., Alam, M., Maccalli, C., Cherif, H., Uddin, S., Steinhoff, M., Marincola, F. M., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01723-z · Cited by 618
T cell receptor (TCR) signaling in health and disease
Shah, K., Al-Haidari, A., Sun, J., & Kazi, J. U. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00823-w · Cited by 604
Metadata
- Authors
- Benmebarek, M.-R., Karches, C. H., Cadilha, B. L., Lesch, S., Endres, S., & Kobold, S.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2019-03-14
- Volume
- 20
- Issue
- 6
- Pages
- 1283
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W2922471907
- Cited by
- 531
- References
- 164
- FWCI
- 18.95
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.